CP-91149

Name: CP-91149
Brand: MedChemExpress
SKU: HY-13525
Rating: 5.0 (4 reviews)

Cat. No.: HY-13525 Purity: 99.80%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

CP-91149 is a GP (glycogen phosphorylase) inhibitor. CP-91149 promotes glycogen resynthesis, but not its overaccumulation. CP-91149 has the potential for Type II (insulin-dependent) diabetes study.

For research use only. We do not sell to patients.

CP-91149 Chemical Structure

CAS No. : 186392-40-5

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 66	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 66	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 95	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 170	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 255	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 360	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

4 Publications Citing Use of MCE CP-91149

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
Hepatocyte	IC₅₀	3172.5 nM Compound: CP-91149	Inhibition of glycogenolysis in rat hepatocytes assessed as GCN-stimulated glycogen breakdown after 5 mins Inhibition of glycogenolysis in rat hepatocytes assessed as GCN-stimulated glycogen breakdown after 5 mins	[PMID: 32527535]
HepG2	IC₅₀	3310.4 nM Compound: CP-91149	Inhibition of glycogenolysis in human HepG2 cells assessed as GCN-stimulated glycogen breakdown after 5 mins Inhibition of glycogenolysis in human HepG2 cells assessed as GCN-stimulated glycogen breakdown after 5 mins	[PMID: 32527535]
Sf9	IC₅₀	0.082 μM Compound: D; CP-91149	Inhibition of human recombinant liver glycogen phosphorylase A expressed in baculovirus infected Sf9 insect cells assessed as release of phosphate from glucose-1- phosphate in presence of 7.5 mM glucose by malachite green based assay Inhibition of human recombinant liver glycogen phosphorylase A expressed in baculovirus infected Sf9 insect cells assessed as release of phosphate from glucose-1- phosphate in presence of 7.5 mM glucose by malachite green based assay	[PMID: 27624527]
Sf9	IC₅₀	110 nM Compound: CP-91149	Inhibition of recombinant human liver glycogen phosphorylase a expressed in baculovirus-infected Sf9 cells using glucose-1-phosphate as substrate in presence of 7.5 mM glucose Inhibition of recombinant human liver glycogen phosphorylase a expressed in baculovirus-infected Sf9 cells using glucose-1-phosphate as substrate in presence of 7.5 mM glucose	[PMID: 32527535]

In Vitro

CP-91149 treatment decreases muscle GP activity by converting the phosphorylated AMP-independent α form into the dephosphorylated AMP-dependent b form and inhibiting GP α activity and AMP-mediated GP b activation^[1].
CP-91149 (10, 30, 50 μM) inhibits brain GP and causes glycogen accumulation in A549 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	Cells were transduced with adenoviruses and incubated in the presence of 25 mM glucose for 2 days.
Concentration:	10 µM (glucose− or glucose+ for 18 h).
Incubation Time:	3 h.
Result:	Promoted the conversion of GP a into GP b, according to α model proposed in hepatocytes.

Western Blot Analysis^[2]

Cell Line:	A549 cells.
Concentration:	0, 10, 30, 50 μM.
Incubation Time:	72 h.
Result:	A significant increase in glycogen accumulation was detected at 10 μM of CP-91149 as compared with untreated cells with a maximal glycogen accumulation at 30 μM. Intracellular glycogen content decreased at 50 μM CP-91149, perhaps explained by additional pharmacological effects of the drug. The dose-dependent accumulation of intracellular glycogen in A549 cells by CP-91149 indicates that CP-91149 inhibits brain GP in tissue culture.

Molecular Weight

399.87

Formula

C₂₁H₂₂ClN₃O₃

CAS No.

186392-40-5

Appearance

Solid

Color

White to off-white

SMILES

O=C(C(N1)=CC2=C1C=CC(Cl)=C2)N[C@@H](CC3=CC=CC=C3)[C@@H](O)C(N(C)C)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (250.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5008 mL	12.5041 mL	25.0081 mL
5 mM	0.5002 mL	2.5008 mL	5.0016 mL
10 mM	0.2501 mL	1.2504 mL	2.5008 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.80%

Select Batch:

Data Sheet (275 KB) SDS (392 KB)

COA (251 KB) HNMR (263 KB) LCMS (92 KB)

Handling Instructions (2659 KB)

References

[1]. Carlos Lerín, et al. Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149. 2004 Mar 15; 378(Pt 3): 1073–1077.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5008 mL	12.5041 mL	25.0081 mL	62.5203 mL
	5 mM	0.5002 mL	2.5008 mL	5.0016 mL	12.5041 mL
	10 mM	0.2501 mL	1.2504 mL	2.5008 mL	6.2520 mL
	15 mM	0.1667 mL	0.8336 mL	1.6672 mL	4.1680 mL
	20 mM	0.1250 mL	0.6252 mL	1.2504 mL	3.1260 mL
	25 mM	0.1000 mL	0.5002 mL	1.0003 mL	2.5008 mL
	30 mM	0.0834 mL	0.4168 mL	0.8336 mL	2.0840 mL
	40 mM	0.0625 mL	0.3126 mL	0.6252 mL	1.5630 mL
	50 mM	0.0500 mL	0.2501 mL	0.5002 mL	1.2504 mL
	60 mM	0.0417 mL	0.2084 mL	0.4168 mL	1.0420 mL
	80 mM	0.0313 mL	0.1563 mL	0.3126 mL	0.7815 mL
	100 mM	0.0250 mL	0.1250 mL	0.2501 mL	0.6252 mL

CP-91149 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CP-91149186392-40-5CP91149CP 91149OthersNSCLCA549diabetesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

CP-91149

Customer Review

CP-91149 Related Antibodies

4 Publications Citing Use of MCE CP-91149

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

CP-91149 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

CP-91149 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report